Jakobsen, JC, Katakam, KK, Schou, A
et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry.
Bielefeldt, AO, Danborg, PB, Gotzsche, PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med
Schneider, LS, Nelson, JC, Clary, CM
et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry
Kasper, S, De Swart, H, Friis Andersen, H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry
Kranzler, HR, Mueller, T, Cornelius, J
et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol
Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA.
Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med.
Friedrich, JO, Adhikari, NK, Beyene, J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol
Pettinati, HM, Oslin, DW, Kampman, KM
et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry
Ravindran, AV, Teehan, MD, Bakish, D
et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol.
De Vries, YA, Roest, AM, Beijers, L, Turner, EH, De Jonge, P. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: a meta-analysis. Eur Neuropsychopharmacol.
Ioannidis, JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med
Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C, Reines, SA. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol.
Nyth, AL, Gottfries, CG, Lyby, K
et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand
Mathews, M, Gommoll, C, Chen, D, Nunez, R, Khan, A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol
Feighner, JP, Overo, K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry
Groenwold, RH, Rovers, MM, Lubsen, J, Van Der Heijden, g. Subgroup effects despite homogeneous heterogeneity test results. BMC Med Res Methodol
Loo, H, Hale, A, D’haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol
Ostergaard, SD. Do not blame the SSRIs: blame the Hamilton Depression Rating Scale. Acta Neuropsychiatr.
Wernicke, JF, Dunlop, SR, Dornseif, BE, Zerbe, RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull.
Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull.
Mendels, J, Kiev, A, Fabre, LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety.
US Food and Drug Administration, Center for Drug Evaluation and Research. Paxil NDA 020031 approval letter, statistical review, 1992.
Fabre, LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry
Hieronymus, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry.
Hieronymus, F, Emilsson, JF, Nilsson, S, Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry.
Bech, P. Is the antidepressant effect of second-generation antidepressants a myth?